Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Oct
02
Today In Oncology
Cleveland Clinic London Appoints Oncology Vice Chief
NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
IARC Panel Provides International Determination on Lung Cancer Screening Benefits and Harms
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo